ID
45573
Descripción
Principal Investigator: Rameen Beroukhim, MD, PhD, Dana-Farber Cancer Institute, Boston, MA 02215, USA MeSH: Meningioma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000552 Meningiomas are the most common primary brain tumor in the US. Although the tumor suppressor gene NF2 is disrupted in approximately half of meningiomas, the complete spectrum of genetic changes in meningiomas remains poorly understood, particularly in the large subset of tumors without NF2 alterations. Therefore we performed whole-genome sequencing from 11 Grade I meningioma tumor-normal pairs and whole-exome sequencing from an additional 6 tumor-normal pairs to identify somatic mutations, insertions-deletions, copy-number alterations and rearrangements. We validated our results by performing focused sequencing across 48 additional meningiomas.
Link
Palabras clave
Versiones (1)
- 24/1/23 24/1/23 - Dr. Christian Niklas
Titular de derechos de autor
Rameen Beroukhim, MD, PhD, Dana-Farber Cancer Institute, Boston, MA 02215, USA
Subido en
24 de enero de 2023
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs000552 Genomic Characterization of Meningiomas
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with meningioma and involved in the "Genomic Characterization of Meningiomas" project.
- Sample ID, subject ID, and sample use variables obtained from participants with meningioma and involved in the "Genomic Characterization of Meningiomas" project.
- Subject ID, age, and sex of participants with meningioma and involved in the "Genomic Characterization of Meningiomas" project.
- Sample ID, body site where sample was collected, analyte type of samples, tumor status, histological type of samples, and whether the sample was obtained from recurrent tumor associated with participants with meningioma and involved in the "Genomic Characterization of Meningiomas" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with meningioma and involved in the "Genomic Characterization of Meningiomas" project.
- Sample ID, subject ID, and sample use variables obtained from participants with meningioma and involved in the "Genomic Characterization of Meningiomas" project.
- Subject ID, age, and sex of participants with meningioma and involved in the "Genomic Characterization of Meningiomas" project.
- Sample ID, body site where sample was collected, analyte type of samples, tumor status, histological type of samples, and whether the sample was obtained from recurrent tumor associated with participants with meningioma and involved in the "Genomic Characterization of Meningiomas" project.
C0680251 (UMLS CUI [1,2])
C0428093 (UMLS CUI [1,2])